ArticleAnnals of surgical oncology2026
Mex3a Stabilizes INHBB mRNA to Activate Smad Signaling and Promote Hepatocellular Carcinoma Metastasis.
Article in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundMex3a has been implicated in tumor progression in several malignancies; however, its clinical significance and biological role in hepatocellular carcinoma (HCC) remain incompletely understood.
methodsMex3a expression patterns and prognostic relevance were first explored using The Cancer Genome Atlas (TCGA) dataset. A single-institution cohort of 59 patients with HCC was then analyzed to evaluate the association between Mex3a expression and clinicopathological characteristics, overall survival (OS), and recurrence-free survival (RFS). Survival outcomes were assessed using Kaplan-Meier analysis and Cox proportional hazards regression. Functional assays in vitro and in vivo were performed to investigate the role of Mex3a in HCC progression.
resultsMex3a was significantly upregulated in hepatocellular carcinoma tissues compared with non-tumor tissues in the TCGA cohort and was associated with poorer overall survival at the univariate level. In the clinical cohort, high Mex3a expression correlated with aggressive clinicopathological features. Multivariate Cox regression analysis demonstrated that Mex3a expression was an independent prognostic factor for overall survival after adjustment for established clinicopathological variables. In contrast, Mex3a expression was not independently associated with recurrence-free survival. Functional experiments revealed that Mex3a promoted malignant phenotypes of HCC cells in vitro and enhanced tumor progression in vivo.
conclusionsMex3a is associated with aggressive tumor behavior and serves as an independent prognostic factor for overall survival, but not recurrence-free survival, in patients with hepatocellular carcinoma. These findings suggest that Mex3a may contribute to disease progression and patient outcomes in HCC.
Indexed as
Identifiers
42479360What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.